App-Quantinova.ai

Inflammatory Risk Status Is Age-Dependent in Women but Not in Men Undergoing Percutaneous Coronary Intervention

Moritz Blum - Transcatheter Cardiovascular Therapeutics (TCT) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

Coronary Plaque Vulnerability in Statin Treated Patients With Elevated LDL-C and hs-CRP: Optical Coherence Tomography Study

Surbhi Chamaria - Transcatheter Cardiovascular Therapeutics (TCT) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Prognostic Value of High-Sensitivity C-Reactive Protein in Percutaneous Coronary Intervention According to Body Mass Index

Niklas Beyhoff - Transcatheter Cardiovascular Therapeutics (TCT) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

TO DETERMINE THE ASSOCIATION OF CENTRAL FAT ACCUMULATION INDICES WITH INFLAMMATORY PARAMETERS IN POLYCYSTIC OVARY SYNDROME

Neha Singh - International Federation of Gynecology and Obstetrics (FIGO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Polycystic Ovary Syndrome

Interleukin

Greater sleep variability is associated with higher systemic inflammation in type 2 diabetes

Sirimon Reutrakul - Associated Professional Sleep Societies (SLEEP) , 2023

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Systemic inflammation

N/A

Prospective study of the metabolic effects of tumescent liposuction

L. Dave - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Risankizumab (RZB) for active psoriatic arthritis (PsA): Integrated subgroup analysis from 2 double-blind, placebo-controlled, phase 3 studies (KEEPsAKE 1 and KEEPsAKE 2)

J. Merola - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Methotrexate

Metabolic Benefits beyond Glycemic Control with Artificial Intelligence, Internet of Things, and Whole-Body Digital Twin: Initial Six Months Results of a Randomized Control Trial

SHASHANK R. JOSHI - American Diabetes Association (ADA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Protein Biomarkers Associated with Dulaglutide and Cardiovascular Events in REWIND

JONATHAN M. WILSON - American Diabetes Association (ADA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Dulaglutide

The Potential of Semaglutide Once-Weekly in Patients without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss after Bariatric Surgery

ANNE LAUTENBACH - American Diabetes Association (ADA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Semaglutide

Normalisation of Glycemic and Extraglycemic Parameters with T2DM Remission—Insights from RCT Enabled by Whole-Body Digital Twin Technology

Paramesh Shamanna - American Diabetes Association (ADA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Diabetes

N/A

A Single Hypoglycemic Event Causes a Prolonged Immune Response

CLEMENTINE E. VERHULST - American Diabetes Association (ADA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Coronary Artery Disease

Insulin

Association of Hepatic Steatosis Index (HSI) and Fibrosis (Fib) -4 Score with Prediabetes Risk in the POP-ABC Study: Potential Mechanisms

BRIGIDA COLON BARRETO - American Diabetes Association (ADA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Nonalcoholic fatty liver disease

Insulin

Non-traditional cardiometabolic risk factors in obese children and adolescents with Metabolic Syndrome

Athanasia Tragomalou - European Society for Paediatric Endocrinology (ESPE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

Interferon Gamma

SERUM VITAMIN D LEVEL AMONG IMMUNOGLOBULIN A NEPHROPATHY PATIENTS AND IT'S ASSOCIATION WITH CLINICAL PARAMETERS

T. NESAM - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

IgA nephropathy

Ergocalciferol

A RANDOMIZED TRIAL OF EFFECT OF CHOLECALCIFEROL SUPPLEMENTATION ON CARDIOVASCULAR DISEASE, INFLAMMATION, AND BONE METABOLISM MARKERS IN CKD: BASELINE CHARACTERISTICS OF FEASIBILITY PHASE

K. Kamboj - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Alkaline phosphatase

CORRELATION OF INTERLEUKIN-6 LEVELS, HIGH SENSITIVITY C-REACTIVE PROTEIN, AND MALNUTRITION INFLAMMATION SCORE WITH QUALITY OF LIFE CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING ROUTINE HEMODIALYSIS

K. ADITIA - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

ILS-969

Inflammation may cause anemia difficult to improve in maintenance hemodialysis patients

Y. Wang - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

Parathyroid hormone

Impact of novel risk factors of atherosclerosis on severity of coronary artery disease in young Indian patients suffering from Myocardial Infarction

A M I T Chaturvedi - European Society of Cardiology (ESC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Coronary Artery Disease

N/A

Meta-Analysis of D-Dimer, hsCRP and Cytokines in COVID-19 Severe/Critical Patients in China

Jie Zhang - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Interleukin-10

Filters

1408 Abstracts